comp_molregno,act_standard_units,act_standard_type,act_activity_comment,act_bao_endpoint,act_type,ass_assay_id,ass_description,ass_assay_type,ass_assay_category,ass_chembl_id,doc_doi,doc_pubmed_id,doc_chembl_id,doc_title,doc_doc_type,doc_abstract,doc_patent_id,coms_canonical_smiles,comp_full_molformula,mold_chembl_id,act_0
BMAIGAHXAJEULY-UKTHLTGXSA-N,%,% Ctrl,Not Active,BAO_0000179,% Ctrl,,116849,ANDROGEN/H Eurofins SafetyScreen44 (BI),In vitro,,,,10.6019/CHEMBL4630904,CHEMBL4630904,Data for DCP probe BI 207127,SGC Frankfurt,"SGC Frankfurt donated chemical probe project: BI 207127 was donated by Boehringer Ingelheim. Website: https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%20207127. Control: BI-7656. References: 1. LaPlante, Steven R., Michael Bös, Christian Brochu, Catherine Chabot, René Coulombe, James R. Gillard, Araz Jakalian, Martin Poirier, Jean Rancourt, Timothy Stammers, Bounkham Thavonekham, Pierre L. Beaulieu, George Kukolj, and Youla S. Tsantrizos. 2014. ‘Conformation-Based Restrictions and Scaffold Replacements in the Design of Hepatitis C Virus Polymerase Inhibitors: Discovery of Deleobuvir (BI 207127)’. Journal of Medicinal Chemistry 57(5):1845–54. doi: 10.1021/jm4011862. PMID: 24159919. 2. Sarrazin, Christoph, Michael Manns, Jose Luis Calleja, Javier Garcia-Samaniego, Xavier Forns, Renee Kaste, Xiaofei Bai, Jing Wu, and Jerry O. Stern. 2016. ‘HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment’. PloS One 11(12):e0168544. doi: 10.1371/journal.pone.0168544. PMID: 28030579 (Secondary paper). 3. Zeuzem, Stefan, Parvez Mantry, Vicente Soriano, Robert J. Buynak, Jean-François Dufour, Paul J. Pockros, David Wright, Peter Angus, Maria Buti, Jerry O. Stern, Werner Kadus, Richard Vinisko, Wulf Böcher, and Federico J. Mensa. 2016. ‘Short Article: Faldaprevir, Deleobuvir and Ribavirin in IL28B Non-CC Patients with HCV Genotype-1a Infection Included in the SOUND-C3 Phase 2b Study’. European Journal of Gastroenterology & Hepatology 28(8):923–26. doi: 10.1097/MEG.0000000000000649. PMID: 27140229 (Secondary paper). 4. Larrey, Dominique, Ansgar W. Lohse, Christian Trepo, Jean-Pierre Bronowicki, Keikawus Arastéh, Marc Bourlière, Jose Luis Calleja, Jerry O. Stern, Gerhard Nehmiz, Nasri Abdallah, Kristi L. Berger, Martin Marquis, Jürgen Steffgen, George Kukolj, and BI 207127 Study Group. 2013. ‘Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C’. Antimicrobial Agents and Chemotherapy 57(10):4727–35. doi: 10.1128/AAC.00565-13. PMID: 23856779 (Secondary paper).","InChI=1S/C34H33BrN6O3/c1-40-26-17-22(10-11-24(26)29(21-6-3-4-7-21)30(40)31-36-18-23(35)19-37-31)32(44)39-34(14-5-15-34)33-38-25-12-8-20(9-13-28(42)43)16-27(25)41(33)2/h8-13,16-19,21H,3-7,14-15H2,1-2H3,(H,39,44)(H,42,43)/b13-9+",0.19,-0.42,107.0
PCJVXTDIDUMIRR-QGZVFWFLSA-N,%,% Ctrl,Not Active,BAO_0000179,% Ctrl,,119988,ANDROGEN/H Eurofins SafetyScreen44 (BI),In vitro,,,,10.6019/CHEMBL4800723,CHEMBL4800723,Data for DCP probe BI-1942,SGC Frankfurt,SGC Frankfurt donated chemical probe project: BI-1942 was donated by Boehringer Ingelheim. Website: https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-1942. Control: No control. References: not published,"InChI=1S/C24H26N4O4/c1-5-17(11-20(29)30)28-23(31)22-18(7-6-8-25-22)27(24(28)32)13-16-12-26(4)19-10-14(2)9-15(3)21(16)19/h6-10,12,17H,5,11,13H2,1-4H3,(H,29,30)/t17-/m1/s1",0.50,-0.87,115.0
PHYBFLAZLZLAGT-NFQMXDRXSA-N,%,% Ctrl,Not Active,BAO_0000179,% Ctrl,,122388,ANDROGEN/H Eurofins SafetyScreen44 (BI),In vitro,,,,10.6019/CHEMBL5058643,CHEMBL5058643,Data for DCP probe BI-2081,SGC Frankfurt,SGC Frankfurt donated chemical probe project: BI-2081 was donated by Boehringer Ingelheim. Website: https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-2081. Control: BI-0340. References: not published,"InChI=1S/C31H33FO7S/c1-18-13-22(40(35,36)12-4-11-37-3)14-19(2)30(18)24-7-9-26(32)31-25(24)8-10-27(31)39-21-5-6-23-20(15-29(33)34)17-38-28(23)16-21/h5-7,9,13-14,16,20,27H,4,8,10-12,15,17H2,1-3H3,(H,33,34)/t20-,27-/m1/s1",0.30,0.04,102.0
QGPXEIMWTKWHMH-DEOSSOPVSA-N,%,% Ctrl,Not Active,BAO_0000179,% Ctrl,,115284,ANDROGEN/H Cerep selectivity data (BI),In vitro,,,,10.6019/CHEMBL4507276,CHEMBL4507276,Data for DCP probe BI 665915,SGC Frankfurt,"SGC Frankfurt donated chemical probe project: BI 665915 was donated by Boehringer Ingelheim. Website: https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI%20665915. Control: BI-0153. References: 1. Takahashi, Hidenori, Doris Riether, Alessandra Bartolozzi, Todd Bosanac, Valentina Berger, Ralph Binetti, John Broadwater, Zhidong Chen, Rebecca Crux, Stéphane De Lombaert, Rajvee Dave, Jonathon A. Dines, Tazmeen Fadra-Khan, Adam Flegg, Michael Garrigou, Ming-Hong Hao, John Huber, J. Matthew Hutzler, Steven Kerr, Adrian Kotey, Weimin Liu, Ho Yin Lo, Pui Leng Loke, Paige E. Mahaney, Tina M. Morwick, Spencer Napier, Alan Olague, Edward Pack, Anil K. Padyana, David S. Thomson, Heather Tye, Lifen Wu, Renee M. Zindell, Asitha Abeywardane, and Thomas Simpson. 2015. ‘Synthesis, SAR, and Series Evolution of Novel Oxadiazole-Containing 5-Lipoxygenase Activating Protein Inhibitors: Discovery of 2-[4-(3-{(r)-1-[4-(2-Amino-Pyrimidin-5-Yl)-Phenyl]-1-Cyclopropyl-Ethyl}-[1,2,4]Oxadiazol-5-Yl)-Pyrazol-1-Yl]-N,N-Dimethyl-Acetamide (BI 665915)’. Journal of Medicinal Chemistry 58(4):1669–90. PMID: 25671290.","InChI=1S/C24H26N8O2/c1-24(19-8-9-19,18-6-4-15(5-7-18)16-10-26-23(25)27-11-16)22-29-21(34-30-22)17-12-28-32(13-17)14-20(33)31(2)3/h4-7,10-13,19H,8-9,14H2,1-3H3,(H2,25,26,27)/t24-/m0/s1",0.45,-1.55,102.0
WPEKGNGDNFRRMH-UHFFFAOYSA-N,%,% Ctrl,Not Active,BAO_0000179,% Ctrl,,116848,ANDROGEN/H Eurofins SafetyScreen44 (BI),In vitro,,,,10.6019/CHEMBL4630903,CHEMBL4630903,Data for DCP probe BI-2540,SGC Frankfurt,"SGC Frankfurt donated chemical probe project: BI-2540 was donated by Boehringer Ingelheim. Website: https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-2540. Control: BI-2439. References: 1. Wang, Xiao-jun, Li Zhang, Xiufeng Sun, Heewon Lee, Dhileepkumar Krishnamurthy, Jeff A. O’Meara, Serge Landry, Christiane Yoakim, Bruno Simoneau, Nathan K. Yee, and Chris H. Senanayake. 2012. ‘Practical Synthesis of A Benzophenone-Based NNRT Inhibitor of HIV-1’. Organic Process Research & Development 16(4):561–66. DOI: 10.1021/op200301h (Synthesis).","InChI=1S/C24H15ClF5NO5/c1-11-18(4-3-16(21(11)27)23(34)35)31-20(32)10-36-19-5-2-14(25)9-17(19)22(33)12-6-13(24(28,29)30)8-15(26)7-12/h2-9H,10H2,1H3,(H,31,32)(H,34,35)",0.30,-1.44,105.0
ZDOBSAPHUUUOHX-OSYLJGHBSA-N,%,% Ctrl,Not Active,BAO_0000179,% Ctrl,,115283,ANDROGEN/H Cerep selectivity data (BI),In vitro,,,,10.6019/CHEMBL4507275,CHEMBL4507275,Data for DCP probe BI-2545,SGC Frankfurt,"SGC Frankfurt donated chemical probe project: BI-2545 was donated by Boehringer Ingelheim. Website: https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/BI-2545. Control: BI-3017. References: 1. Kuttruff, Christian A, Marco Ferrara, Tom Bretschneider, Stefan Hoerer, Sandra Handschuh, Bernd Nosse, Helmut Romig, Paul Nicklin, and Gerald J Roth. 2017. ‘Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo’. ACS Medicinal Chemistry Letters 8(12):1252–57. PMID: 29259743 .","InChI=1S/C23H19F6N5O3/c24-22(25,26)13-3-11(4-14(6-13)23(27,28)29)10-37-21(36)34-8-16-15(17(16)9-34)7-30-20(35)12-1-2-18-19(5-12)32-33-31-18/h1-6,15-17H,7-10H2,(H,30,35)(H,31,32,33)/t15-,16-,17+",0.48,-1.14,103.0
